Colorado Passes Law Allowing Doctors to Prescribe Cannabis in Place of Opioids

Denver-based NanoSphere Health Sciences Offers Alternative Cannabis Medication to Help Replace Opioids for Patients Suffering from Chronic Pain

DENVER (DATE)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) CEO Robert Sutton today congratulated the Governor and Legislature of Colorado for their passage of an historic bill allowing physicians to recommend cannabis instead of opioids for relief of pain.

Read More
Samuel TheilComment
NanoSphere and Vertical Unveil the Future of Cannabis at Hall of Flowers Trade Show

Award-Winning Evolve Formulas Transdermal NanoSerum™ Has Hit Dispensary Shelves in the Golden State

DENVER (DATE)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) (‘NanoSphere or ‘the Company’) parent company of cannabis brand Evolve Formulas, in partnership with Vertical™, the largest fully integrated company in the legal medical cannabis industry, will formally unveil the Evolve Formulas line for the California market at the Hall of Flowers trade show on April 30.

Read More
Samuel TheilComment
NanoSphere Health Sciences Has Received Notice of Allowance for a Patent for its Breakthrough Nanoparticle Encapsulations of NSAIDs

Allowance for the patent marks significant advancement for the treatment of pain and inflammation

Denver (April 24, 2019) – Biotechnology leader NanoSphere Health Sciences, LLC (CSE: NSHS) (OTC: NSHSF) has received formal Notice of Allowance from the Canadian Intellectual Property Office (CIPO) for Application 2,970,91, covering “The Method of Treating Inflammatory Disorders and Global Inflammation with Phospholipid Nanoparticle Encapsulations of NSAIDs.”

Read More
Samuel TheilComment
NanoSphere Products Approved for Sale in California Cannabis Market

Vancouver (April 2, 2019)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) is pleased to announce its Evolve cannabis products will be available for purchase in California for the first time, after receiving final approval by the State of California.

NanoSphere’s Evolve Formula NanoSerum™ is expected to hit store shelves in the Los Angeles area by April 8th.

Read More
Samuel TheilComment
NanoSphere Closes $2million Private Placement Offering

DENVER (February 21, 2019)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) (“Nanosphere” or “the Company”) is pleased to announce that it has closed its second and final tranche of its non-brokered private placement announced on Feb. 11, 2019. Pursuant to the first tranche, the company issued 6,666,394 units at a price of 30 cents per unit for gross proceeds of $1,999,918.20.

Read More
Samuel TheilComment
NanoSphere Signs Definitive Licensing Agreement in Oregon

Partnership with Cascade Pure Brings Disruptive Evolve Formulas Technology to $550 Million Oregon Cannabis Market

DENVER (Feb. 20, 2019)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) (“NanoSphere” or “the Company”) is pleased to announce the signing of a definitive Licensing Agreement with Oregon cannabis company Cascade Pure, LLC. The Agreement gives Cascade Pure the exclusive right to produce and distribute Evolve Formulas products in the State of Oregon.

Read More
Samuel TheilComment
The Cannabis Company That Really DELIVERS

As the cannabis industry matures, both the opportunities and the challenges in this new sector are starting to crystallize. But what is a “challenge” for the cannabis industry as a whole can spell opportunity for individual companies. Perhaps no niche of the industry illustrates this point better than cannabis delivery technology.

Read More
Samuel TheilComment
NanoSphere Partners with Gofire to Debut DoseCode-Enabled Products in Colorado Market

—Scannable Technology Grants Patients Access to Descriptions, Reviews and Dosing Information for Evolve Formulas Products—

DENVER (December 6, 2018) – NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF), the biotechnology leader behind the patented NanoSphere Delivery System™, today announced the launch of its new, DoseCode-enabled Evolve Formulas products in the Colorado market, leveraging industry-first technology from Denver-based healthcare startup Gofire.

Read More
Samuel TheilComment
Nanosphere Closes $1.335m First Tranche of Private Placement

DENVER (December 14, 2018) – NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) the biotechnology leader behind the patented NanoSphere Delivery System™, is pleased to announce a first tranche closing of its non-brokered private placement announced November 28, 2018.  Pursuant to the first tranche, the company issued 4,452,254 Units at a price of $0.30 per Unit for gross proceeds of CAD $1,335,676. 

Read More
Samuel TheilComment
NanoSphere Announces Revised Terms for Private Placement

DENVER--(BUSINESS WIRE)--NanoSphere Health Sciences, Inc. (CSE: NSHS) (OTC: NSHSF) announces revised terms for its non-brokered private placement previously announced on Nov. 16, 2018. The offering will consist of up to 7,500,000 units at a price of $0.30 per unit for gross proceeds of up to CAD $2,250,000. Each unit will be comprised of a common share and a full purchase warrant exercisable to purchase a further common share at a price of $0.50 cents for a period of 24 months, subject to accelerated expiry if the Company’s shares trade at or above $0.75 for 15 consecutive days.

Read More
Samuel TheilComment
Nanosphere Announces $2.25 Million Financing for Rapid Expansion of Cannabis Product Line

DENVER (November 16, 2018)– NanoSphere Health Sciences Inc. (CSE: NSHS) (OTC: NSHSF) is pleased to announce a non-brokered private placement of up to CAD $2,250,000. The proceeds will be used to expand our award-winning Evolve Formulas cannabis products into more markets in the US, Canada, and outside of North America.  Funds will also be used to develop new products, increase production in the states that Evolve Products are available in, as well as for general working capital.

Read More
Samuel TheilComment